Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IeM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, De Marzo AM, Terracciano L, Torbenson M, Meeker AK.

Am J Pathol. 2011 Oct;179(4):1608-15. doi: 10.1016/j.ajpath.2011.06.018. Epub 2011 Sep 1.

2.

The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression.

Subhawong AP, Heaphy CM, Argani P, Konishi Y, Kouprina N, Nassar H, Vang R, Meeker AK.

Mod Pathol. 2009 Nov;22(11):1423-31. doi: 10.1038/modpathol.2009.125. Epub 2009 Sep 4.

3.

A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.

Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR.

Clin Cancer Res. 2005 Jan 1;11(1):217-25.

4.

Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.

Venturini L, Daidone MG, Motta R, Collini P, Spreafico F, Terenziani M, Piva L, Radice P, Perotti D, Zaffaroni N.

Genes Chromosomes Cancer. 2011 Oct;50(10):823-9. doi: 10.1002/gcc.20903. Epub 2011 Jul 18.

PMID:
21769957
5.

Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas.

Matsuo T, Shay JW, Wright WE, Hiyama E, Shimose S, Kubo T, Sugita T, Yasunaga Y, Ochi M.

J Bone Joint Surg Am. 2009 Apr;91(4):928-37. doi: 10.2106/JBJS.G.01390.

PMID:
19339578
6.

Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.

Liau JY, Tsai JH, Yang CY, Lee JC, Liang CW, Hsu HH, Jeng YM.

Hum Pathol. 2015 Sep;46(9):1360-6. doi: 10.1016/j.humpath.2015.05.019. Epub 2015 Jun 5.

PMID:
26190196
7.

Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers.

Pal D, Sharma U, Khajuria R, Singh SK, Kakkar N, Prasad R.

Gene. 2015 May 15;562(2):145-51. doi: 10.1016/j.gene.2015.02.079. Epub 2015 Mar 11.

PMID:
25769384
8.

Telomeres and telomerase in sarcomas.

Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M.

Anticancer Res. 2009 Oct;29(10):3833-6. Review.

9.

Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.

Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH, Ladanyi M.

Genes Chromosomes Cancer. 2004 Oct;41(2):155-62.

PMID:
15287028
10.

Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies.

Gocha AR, Nuovo G, Iwenofu OH, Groden J.

Am J Pathol. 2013 Jan;182(1):41-8. doi: 10.1016/j.ajpath.2012.10.001.

11.

Alternative lengthening of telomeres can be maintained by preferential elongation of lagging strands.

Min J, Wright WE, Shay JW.

Nucleic Acids Res. 2017 Mar 17;45(5):2615-2628. doi: 10.1093/nar/gkw1295.

12.

Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.

Gocha AR, Harris J, Groden J.

Mutat Res. 2013 Mar-Apr;743-744:142-50. doi: 10.1016/j.mrfmmm.2012.11.006. Epub 2012 Dec 3. Review.

13.

A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT).

Jeitany M, Pineda JR, Liu Q, Porreca RM, Hoffschir F, Desmaze C, Silvestre DC, Mailliet P, Junier MP, Londoño-Vallejo A, Ségal-Bendirdjian E, Chneiweiss H, Boussin FD.

Int J Cancer. 2015 Apr 1;136(7):1546-58. doi: 10.1002/ijc.29171. Epub 2014 Sep 11.

14.

Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R.

Fujiwara M, Kamma H, Wu W, Yano Y, Homma S, Satoh H.

Int J Oncol. 2006 Aug;29(2):445-51.

PMID:
16820888
15.

Caenorhabditis elegans POT-2 telomere protein represses a mode of alternative lengthening of telomeres with normal telomere lengths.

Cheng C, Shtessel L, Brady MM, Ahmed S.

Proc Natl Acad Sci U S A. 2012 May 15;109(20):7805-10. doi: 10.1073/pnas.1119191109. Epub 2012 Apr 30.

16.

Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma.

Lee YK, Park NH, Lee H.

Int J Gynecol Cancer. 2012 Mar;22(3):434-41. doi: 10.1097/IGC.0b013e31823ca017.

PMID:
22266933
17.

Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.

Bower K, Napier CE, Cole SL, Dagg RA, Lau LM, Duncan EL, Moy EL, Reddel RR.

PLoS One. 2012;7(11):e50062. doi: 10.1371/journal.pone.0050062. Epub 2012 Nov 20.

18.

The telomere-associated homeobox-containing protein TAH1/HMBOX1 participates in telomere maintenance in ALT cells.

Feng X, Luo Z, Jiang S, Li F, Han X, Hu Y, Wang D, Zhao Y, Ma W, Liu D, Huang J, Songyang Z.

J Cell Sci. 2013 Sep 1;126(Pt 17):3982-9. doi: 10.1242/jcs.128512. Epub 2013 Jun 26.

19.

Alternative lengthening of telomeres in cancer stem cells in vivo.

Bojovic B, Booth RE, Jin Y, Zhou X, Crowe DL.

Oncogene. 2015 Jan 29;34(5):611-20. doi: 10.1038/onc.2013.603. Epub 2014 Feb 17.

20.

Alternative lengthening of telomeres does exist in various canine sarcomas.

Kreilmeier T, Sampl S, Deloria AJ, Walter I, Reifinger M, Hauck M, Borst LB, Holzmann K, Kleiter M.

Mol Carcinog. 2017 Mar;56(3):923-935. doi: 10.1002/mc.22546. Epub 2016 Sep 22.

PMID:
27585244

Supplemental Content

Support Center